Other Pigmentary Disorders in Darker Skin Types
pigmentary disordersNext Steps in Derm, in partnership with Skin of Color Update, interviewed Dr. Heather Woolery-Lloyd, director of the Skin of Color Division for the University of Miami Department of Dermatology. There’s more to pigmentary disorders than melasma and vitiligo. Watch as Dr. Woolery-Lloyd outlines disorders of hyperpigmentation and hypopigmentation. Learn why time matters in treating lichen planus …
pigmentary disorders
Valacyclovir Therapeutic Cheat Sheet
ValacyclovirHerpesviridae is a family of ubiquitous viral pathogens leading to a wide array of diseases in humans, and includes viruses such as herpes simplex virus 1 (HSV-1) and 2 (HSV-2), herpes/varicella zoster virus (VZV), Epstein-Barr virus (EBV), cytomegalovirus (CMV) and herpes viruses 6 (HHV-6), 7 (HHV-7) and 8 (HHV-8). Mucocutaneous herpetic infections are frequently encountered in dermatology, and s …
Valacyclovir
Keloids: Medical Treatment Strategies with Dr. Kerby
keloidsNext Steps in Derm, in partnership with Skin of Color Update, interviewed Dr. Eva Kerby, assistant professor of clinical dermatology at Weill Cornell Medical College. Dr. Kerby shares her preferred medical treatment options for  keloids, and why it’s important to set treatment expectations with patients. Watch as Dr. Kerby shares tips for good injection technique and how to treat larger, nodul …
keloids
Reversible Hair Loss in Lichen Planopilaris | Great Cases from the JDD
LICHEN PLANOPILARISINTRODUCTION Lichen planopilaris (LPP) is a cicatricial alopecia that presents with patchy or diffuse hair loss at the vertex or parietal scalp. Although there is no gold standard therapy, most interventions are immune modulating and aimed at reducing inflammation and terminating the scarring process to prevent further fibrosis.3 Even amongst patients who respond to therapy, hair loss at alopeci …
LICHEN PLANOPILARIS
Omalizumab Therapeutic Cheat Sheet
OmalizumabChronic idiopathic urticaria is urticaria for greater than 6 weeks without an identifiable trigger. Cases relapse in 20% of patients for more than 5 years and be difficult to manage; however, omalizumab is a recently approved option for treatment of chronic idiopathic urticaria showing beneficial outcomes.1 Omalizumab is an injectable monoclonal antibody that has been FDA approved not just for chr …
Omalizumab
error

Enjoy this blog? Please spread the word :)